Controlled phase III trial of adjuvant combination chemotherapy of gemcitabine and capecitabine, versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma

Bookmark and Share
Published: 3 Jun 2016
Views: 1638
Prof John P. Neoptolemos - University of Liverpool, Liverpool, UK

Prof Neoptolemos presents at ASCO 2016, a European phase III trial, one of the largest ever conducted in pancreatic cancer, which showed that adding the oral drug capecitabine chemotherapy to gemcitabine prolongs survival without increased toxicity.

Read the news story for more.